Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-16
2011-08-16
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S143000
Reexamination Certificate
active
07998978
ABSTRACT:
The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein: R1, R2, Z1, t, and ring A are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of JNK, such as diabetes, the method comprising administering to a mammal an effective amount of a compound of formula (I).
REFERENCES:
patent: 3535321 (1970-10-01), Dunn
patent: WO01/17995 (2001-03-01), None
patent: WO01/81311 (2001-11-01), None
patent: WO02/079197 (2002-10-01), None
patent: WO2004/065378 (2004-08-01), None
patent: WO2007/000240 (2007-01-01), None
Zdrojewski et al. A General Approach to 3-Aminoisoquinoline, Its N-Mono-and N,N-Disubstituted Derivatives.1995, Tetrahedron, 51,12439-12444.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 and 365.
Morissette et al. “High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.” 2004, Advanced Drug Delivery Reviews, 56, 275-300.
Neumeyer et al., 3-(Dialkylaminoalkylamino)isoquinolines as Potential Antimalarial Drugs, J. of Medicinal Chemistry, 1970, V 13, No. 5, p. 999-1002.
Still, et al., Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution, J. Org. Chem.,1978, vol. 43, No. 14, p. 2923-25.
Avraamides et al., Elimination Reactions of Stilbene Dibromides. Dehydrobromination by Acetate, Cyaninde or Chloride Ions in Dimethylfo . . . , Aust. J. Chem., 1983, V36, p. 1705-17.
van Benthem, A Practical synthesis of Geometrically Pure N-Boc-Protected Primary Allylic Amines, Synlett,1994 p. 368-370.
Patani, et al., Bioisosterism: A Rational Approach in Drug Design, Chemical Review, 1996, vol. 96, p. 3147-3176.
Zdrojewski et al., A general Approach to 3-Aminoisoquinoline, its N-Mono-N,N-Disubstituted Derivatives, Tetrahedron, 1995,V51, No. 45, p. 12439-444.
Gibson, et al., epidermal Growth Factor receptor Tyrosine Kinase:Structure-Activity Relationships and Antitumour Activity of . . . , Bioorg. & Med. Chem. Letters, V7, p. 2723-28.
Minden et al., Regulation and Function of the JNK subgroup of MAP Kinases, Biochimica et Beiophysica Acta 1333, 1997, F85-F104.
Thavonekham, A Practical synthesis of Ureas from Phenyl Carbamates, Synthesis, 1997, p. 1189-94.
Tomassy, et al., Stereoselective Routes to E and Z Straight-Shcin Primary Allylic amines', Synthetic Commun., V28:7, p. 1201-14.
Greene, et al., The Role of Protective Groups in Organic Synthesis, Protective Groups in Organic Synthesis, 1999, p. 1-16.
Frutos, et al., Synthesis of Bezo[b]phenanthridines and Related Naturally occurring 2-Aryl . . . , Eur. J. Org. Chem, 2001 p. 163-71.
Hirosumi et al., A Central Role for JNK in obesity and insulin resistance, Nature, 2002, V420, p. 333-36.
Swanson, et al., Identification and Biological Evaluation of 4-3-Trifluoromethylpyridin-2-yl) . . . , J. Med. chem 2005, V48, p. 1857-72.
Kanuma, et al., Discovery of 4-(dimethylamino)quinazolines as potent . . . , Bioorg. Med. Chem. Lett, 2005, V.15, 2565-69.
Bathini, et al., 2-Aminoquinazoline inhibitors of cyclin-dependent kinases, Bioorg. Med. Chem. Lett, 2005, V15 p. 3881-85.
Graczyk, et al., The neuroprotective action of JNK3 inhibitors based on the 6,7-dihydro- . . . Bioorg. Med. Chem. Lett., 2005, V15, 4666-4670.
Sasse, 1978 Communications, p. 379-382.
Gibson, KH., et al.; Bioorganic & Medicinal Chemistry Letters, vol. 7, No. 21, pp. 2723-2728, 1997.
Beata Tomassy and Andrzej Zwierzak; Synthetic Communications, vol. 28 (7), pp. 1201-1214, 1998.
Denmark, et al., (E)-3-(Trimethylsilyl)-2-propen-1-ol. An improved preparation, J. Org. Chem., 1982, vol. 47, p. 4595-97.
Huang Liming
Liu Song
Lunney Elizabeth A.
Planken Simon P.
McDowell Brian
Pfizer Inc.
Sabnis Ram W.
Wilson James O
LandOfFree
Substituted 2-amino-fused heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 2-amino-fused heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 2-amino-fused heterocyclic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2767720